domingo, 27 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 20, 2025

Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights

View original at globenewswire.com
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights Burlingame, CA, Nov…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • North America is expected to retain its dominance, capturing 38.3% of the global market share in 2025

    80% confidence

  • More than 1 billion people will be living with obesity by 2030

    80% confidence

  • The global anti-obesity drug industry is set to experience strong growth, owing to rising prevalence of obesity, escalating health and wellness awareness, growing popularity of combination therapies, and advancements in new drug formulations

    80% confidence

  • GLP-1 receptor agonists like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are revolutionizing obesity treatment

    80% confidence

  • Asia Pacific, with an estimated share of 24.2% in 2025, is anticipated to emerge as a highly lucrative market for anti-obesity drug companies

    80% confidence

  • The Global Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032

    80% confidence

  • High cost of treatment and growing competition from non-pharmacological approaches might slow down market growth to some extent during the forecast period

    80% confidence

  • GLP-1 receptor agonists segment is expected to account for a market share of 22.1% in 2025

    80% confidence

  • The market will exhibit a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032

    80% confidence

  • Prescription drugs segment is slated to dominate the industry, accounting for nearly two-thirds of the global anti-obesity drug market share by 2025

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights — Source | Via News | es.VIA.NEWS